Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.13 -0.14 (-0.26%)
Streaming Delayed Price Updated: 3:06 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
31 32 Next >
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
7 Blue-Chip Stocks to Buy in May 2023
While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy. 
Via InvestorPlace
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating  
Via Benzinga
7 Stock Upgrades and Downgrades Alerts You Cannot Ignore
Analyst stock upgrades and downgrades caught the market's attention in the last week and putting investors on notice for buys and sells. 
Via InvestorPlace
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Benzinga 
Via Benzinga
Sanofi (SNY) Q1 2023 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2023. 
Via The Motley Fool
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public... 
Via Benzinga
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently... 
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Earnings Outlook For Sanofi
Via Benzinga
Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Sanofi (NASDAQ: SNY) Climbs to New 52-Week High
Via Investor Brand Network
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
AbbVie Stock Shows Improved Relative Price Strength
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see. 
Via Investor's Business Daily
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
Via Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... 
Via Benzinga
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
Via Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday 
Via Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
The market sell-off over the past year hasn't stopped these healthcare giants from rallying. 
Via The Motley Fool
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years. 
Via The Motley Fool
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.